SIRT2
HDAC6型
乙酰化
锡尔图因
化学
微管蛋白
神经退行性变
组蛋白脱乙酰基酶
生物化学
组蛋白
计算生物学
细胞生物学
生物
基因
微管
医学
疾病
病理
作者
Laura Sinatra,Anja Vogelmann,Florian Friedrich,Margarita A. Tararina,Emilia Neuwirt,Arianna Colcerasa,Philipp König,Lara Toy,Talha Z. Yesiloglu,Sebastian Hilscher,Lena Gaitzsch,Niklas Papenkordt,Shiyang Zhai,Lin Zhang,Christophe Romier,Oliver Einsle,Wolfgang Sippl,Mike Schutkowski,Olaf Groß,Gerd Bendas
标识
DOI:10.1021/acs.jmedchem.3c01385
摘要
Dysregulation of both tubulin deacetylases sirtuin 2 (Sirt2) and the histone deacetylase 6 (HDAC6) has been associated with the pathogenesis of cancer and neurodegeneration, thus making these two enzymes promising targets for pharmaceutical intervention. Herein, we report the design, synthesis, and biological characterization of the first-in-class dual Sirt2/HDAC6 inhibitors as molecular tools for dual inhibition of tubulin deacetylation. Using biochemical in vitro assays and cell-based methods for target engagement, we identified Mz325 (31) as a potent and selective inhibitor of both target enzymes. Inhibition of both targets was further confirmed by x-ray crystal structures of Sirt2 and HDAC6 in complex with building blocks of 31. In ovarian cancer cells, 31 evoked enhanced antiproliferative effects compared to single or combination treatment with the unconjugated Sirt2 and HDAC6 inhibitors. Thus, our dual Sirt2/HDAC6 inhibitors are important new tools to study the consequences and the therapeutic potential of dual inhibition of tubulin deacetylation.
科研通智能强力驱动
Strongly Powered by AbleSci AI